Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Carboplatin/Paclitaxel in Frail SCCHN
NCT03723967Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- May 2019
- Primary completion
- May 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Centre Léon Bérard. Started May 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03723967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723967.